Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
91
resultados
Última actualización
04/10/2025 [07:45:00]
Resumen de: CN120737217A
本发明提供了一种亚单位疫苗及其制备方法与应用。所述疫苗包括式（1）的融合蛋白，D0a‑D1a‑Linker‑HA‑Linker‑D1b‑D0b（1）其中，D0a和D0b分别为细菌鞭毛蛋白FliC的D0结构域或其功能性片段的N端部分和C端部分，D0a和D0b组成细菌鞭毛蛋白FliC的D0结构域或其功能性片段；D1a和D1b分别为细菌鞭毛蛋白FliC的D1结构域或其功能性片段的N端部分和C端部分，D1a和D1b组成细菌鞭毛蛋白FliC的D1结构域或其功能性片段；HA为流感病毒HA蛋白的抗原表位或其功能性片段，linker为连接子，‑为肽键或其他化学键。可以用于流感病毒的净化工作，安全有效，具有较高的应用价值。
Resumen de: WO2025202803A1
The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.
Resumen de: US2025304662A1
Among the various aspects of the present disclosure is the provision of FimH inhibiting compositions and methods of use thereof. FimH inhibiting compositions that target and inhibit FimH, including monoclonal antibodies, are described. Methods of identifying FimH inhibiting antibodies are also described. Further, a method of treating bacterial infections, including urinary tract infections, is described.
Resumen de: EP4623922A2
The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharmaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.
Resumen de: CN120718821A
本发明公开了一种基因工程菌及其在抗革兰氏阴性菌感染中的应用。所述基因工程菌为在出发菌株中利用细菌表面展示系统过表达菌毛黏附素、肠道消化酶识别位点和细菌素。本发明的基因工程菌能在肠道中肠激酶的作用下，释放有活性的细菌素并暴露出菌毛黏附素，并实现杀灭肠道内的鼠伤寒沙门氏菌，及预防鼠伤寒沙门氏菌的再次定植的效果。
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: WO2025199081A1
The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and/or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.
Resumen de: WO2025199547A1
A composition and method for therapeutic or prophylactic treatment of birds includes a mixture of IgY antibodies derived from one or more eggs laid by one or more avian species, wherein each of the one or more avian species have been vaccinated with one or more of the plurality of antigens. The mixture of IgY antibodies can be combined with a protective material that includes colostrum.
Resumen de: US2025295747A1
The present disclosure provides compositions and methods for making and using Salmonella recombinant bacteria that express LPS O78 antigen and/or virulence factors of avian pathogenic Escherichia coli (APEC) as vaccines to prevent colibacillosis infections.
Resumen de: EP4621058A1
The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuated Salmonella strain according to the present disclosure is designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response, whereby tumor sizes in metastatic cancers as well as primary cancers can be significantly inhibited. Thus, the strain can be advantageously used in a prophylactic or therapeutic composition for improving survival rates.
Resumen de: WO2024180083A1
The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an autotransporter comprising transmembrane linker and a trans- porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
Resumen de: AU2024217948A1
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2025189290A1
The present invention relates to the use of bacteria, such as Salmonella, as a carrier for an expression vector that encodes all or a portion of replicon proteins from a positive stranded virus, wherein expression of the replicon proteins is under the control of eukaryotic and/or prokaryotic promoters, and wherein expression of a payload is under the control of a sub-genomic promoter. Also provided are methods of using the bacteria comprising the vector in therapeutics and vaccines.
Resumen de: CN120622690A
本发明涉及生物技术处理污水的技术领域，尤其涉及一种含磷污水的处理方法。所述方法包括以下步骤：1）调节含磷污水的pH值为7.0‑7.5，补充乙酸钠和铵盐至浓度分别为0.1‑0.2g/L和0.01‑0.04g/L；2）在上述污水中接种聚磷菌，接种浓度为2‑5%；3）对污水中的磷污染物进行检测，符合排污标准后，排出污水。本发明对微生物进行改造，显著提高了菌体体内多聚磷酸物的水平，其改造相较于野生型提升了87.6%；导入RcsA基因后对于其荚膜产量有明显提升，而且将重度磷污染的污水中磷的含量降低到8.4mg/L，为其在商业中使用奠定了基础。
Resumen de: CN120605324A
本发明涉及一种猪源细菌多糖‑病毒蛋白结合疫苗及其制备方法和应用，属于动物疫苗技术领域。该疫苗以猪源细菌多糖和病毒蛋白为原料，通过生物素‑亲和素体系偶联形成多糖‑病毒蛋白结合物；其中病毒蛋白选自猪瘟病毒E2蛋白、猪圆环病毒2型Cap蛋白、猪伪狂犬病毒gD蛋白等蛋白中的一种，猪源细菌多糖选自猪链球菌荚膜多糖、猪多杀性巴氏杆菌荚膜多糖等多糖中的一种。该疫苗能同时诱导机体产生针对猪源细菌荚膜多糖和病毒蛋白的高水平IgG抗体，实现对猪源细菌和病毒感染的协同免疫保护，具有广谱交叉免疫效果。
Resumen de: KR20240015036A
The present invention relates to a recombinant expression vector for secretion of ifn-03b2# protein and an attenuated salmonella strain transformed by the same. provided are a recombinant expression vector comprising a flgm gene, an ifn-03b2# gene, and a flhdc gene, an attenuated salmonella strain transformed by the same, and a pharmaceutical composition for treating cancer comprising the attenuated salmonella strain as an active ingredient.
Resumen de: AU2024220779A1
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: KR20250131847A
본 발명은 대장균 및 살모넬라 균을 동시에 감염하며, 생물막 제거와 병원체 오염 식품 제어에 효과적인 용균성 박테리오파지 vB_ESM-pEJ01에 관한 것으로, 본발명에 따른 파지 및/또는 조성물은 시가 독소 생성 대장균을 제거하기 위한 항균제로 이용될 수 있다.
Resumen de: US2025277250A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a simple that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN120550103A
一种基于细菌外膜囊泡的口服疫苗制备方法及其应用，可有效应用于制备预防或治疗肠道黏膜病原体感染的药物，克服传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先制备粪产碱杆菌的细菌外膜囊泡，然后制备DSPE‑PEG‑antigen，将两者混合后搅拌，制得OMV‑DSPE‑PEG‑antigen，取菊粉溶于PBS中，加热振荡，冷却至室温，加入OMV‑DSPE‑PEG‑antigen，搅拌，放置，得成品口服疫苗。制备工艺简单，方法稳定可靠，易操作，生产成本低，制备的基于细菌外膜囊的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，经济和社会效益显著。
Resumen de: WO2024155027A1
The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer efficacy, and thus can be used as a therapeutic agent for cancer together with or independently of existing anti-cancer drugs.
Resumen de: WO2025171792A1
Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.
Resumen de: US2025261659A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
Nº publicación: WO2025175111A1 21/08/2025
Solicitante:
AEGIS FOODS LLC [US]
AEGIS FOODS LLC
Resumen de: WO2025175111A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
BOPI
Sede Electrónica
